ProMIS Neurosciences Inc. - 8-K Filing

ProMIS Neurosciences updates corporate presentation highlighting PMN310 Phase 1b clinical trial timeline and cash runway. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PMN

Read the full article at SEC EDGAR

Part of the story Septerna, Inc. - 8-K Filing (3 articles)

More Regulatory news